CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse
详细信息 查看全文
- 作者：Roni Tamari1 ; 2 ; ronitamari@yahoo.com" class="auth_mail" title="E-mail the corresponding author ; Stephen S. Chung3 ; Esperanza B. Papadopoulos1 ; 2 ; Ann A. Jakubowski1 ; 2 ; Patrick Hilden4 ; Sean M. Devlin4 ; Jenna D. Goldberg1 ; 2 ; Miguel-Angel Perales1 ; 2 ; Doris M. Ponce1 ; 2 ; Craig S. Sauter1 ; 2 ; Molly A. Maloy1 ; Dara Y. Herman1 ; Virginia Klimek3 ; James W. Young1 ; 2 ; Richard J. O'Reilly2 ; 5 ; Sergio A. Giralt1 ; 2 ; Hugo Castro-Malaspina1 ; 2
- 关键词：CD34 selection ; Advanced myelodysplastic syndromes ; Acute and chronic GVHD ; Relapse ; Relapse/chronic GVHD-free survival
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：21
- 期：12
- 页码：2106-2114
- 全文大小：633 K
文摘
- •
CD34-selected stem cell transplantation offers long-term survival for patient with advanced MDS.
- •
CD34-selected stem cell transplantation has low incidence of acute and chronic GVHD.
- •
Relapse rates after CD34-selected stem cell transplantation are not higher compared with unmodified transplants.
- •
Infections are the main cause of mortality after CD34-selected stem cell transplantation.